Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced the acceptance of two presentations at the Alzheimer's Association International Conference 2015 (AAIC) being held in Washington, D.C. from July 18-23, 2015.
The data will be presented via oral and poster presentations as follows:
Efficacy of RVT-101 in Mild-Moderate Alzheimer's Disease: Completer Analysis (Oral Presentation):
The Efficacy of RVT-101, a 5-HT6 Receptor Antagonist, As an Adjunct to Donepezil in Adults with Mild-to-Moderate Alzheimer's Disease: Completer Analysis of a Phase 2b Study will be presented during the Developing Topics Session: Clinical Trial Results on Wednesday, July 22, 2015, 2:00-3:30 p.m. (Hall E; # DT-01-04).
Efficacy of RVT-101 in Mild-Moderate Alzheimer's Disease: Responder Analysis (Poster Presentation):
RVT-101, a 5-HT6 Receptor Antagonist, As Adjunctive Therapy with Donepezil in Adults with Mild-to-Moderate Alzheimer's Disease: Responder Analysis will be presented during the Therapeutics: Clinical poster session on Wednesday July 22, 2015, 9:30 a.m. - 4:15 p.m. (Exhibit Hall E; # P4-302).
The molecular underpinnings by which traumatic brain injury increases Alzheimer's disease risk